RadNet, Inc. (RDNT) stock
RDNTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3055% above fair value
$76.04−2.04 (-2.61%)
Close on Nov 12, 2026Market cap $5.98BP/E –Yield –
RadNet EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
RadNet's EPS for the twelve months ending Sep 30, 2026 was -$0.29. For fiscal 2025 it was -$0.25, down 725.0% from the year before. The highest annual figure on record is $1.52 in fiscal 2012.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.25 | -725.0% |
| FY2024 | Dec 31, 2024 | $0.04 | -20.0% |
| FY2023 | Dec 31, 2023 | $0.05 | -70.6% |
| FY2022 | Dec 31, 2022 | $0.17 | -63.0% |
| FY2021 | Dec 31, 2021 | $0.46 | – |
| FY2020 | Dec 31, 2020 | -$0.29 | -200.0% |
| FY2019 | Dec 31, 2019 | $0.29 | -56.1% |
| FY2018 | Dec 31, 2018 | $0.66 | – |
| FY2017 | Dec 31, 2017 | $0.00 | -100.0% |
| FY2016 | Dec 31, 2016 | $0.15 | -11.8% |
| FY2015 | Dec 31, 2015 | $0.17 | +466.7% |
| FY2014 | Dec 31, 2014 | $0.03 | -40.0% |
| FY2013 | Dec 31, 2013 | $0.05 | -96.7% |
| FY2012 | Dec 31, 2012 | $1.52 | +700.0% |
| FY2011 | Dec 31, 2011 | $0.19 | – |
| FY2010 | Dec 31, 2010 | -$0.35 | – |
| FY2009 | Dec 31, 2009 | -$0.06 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.05 | -28.6% |
| Q2 FY2026 | Jun 30, 2026 | $0.10 | -47.4% |
| Q1 FY2026 | Mar 31, 2026 | -$0.43 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.01 | -114.3% |
| Q3 FY2025 | Sep 30, 2025 | $0.07 | +75.0% |
| Q2 FY2025 | Jun 30, 2025 | $0.19 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.51 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.07 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.04 | -84.0% |
| Q2 FY2024 | Jun 30, 2024 | -$0.04 | -133.3% |
| Q1 FY2024 | Mar 31, 2024 | -$0.04 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.03 | – |
| Q3 FY2023 | Sep 30, 2023 | $0.25 | +2400.0% |
| Q2 FY2023 | Jun 30, 2023 | $0.12 | -7.7% |
| Q1 FY2023 | Mar 31, 2023 | -$0.36 | -820.0% |
| Q4 FY2022 | Dec 31, 2022 | -$0.02 | -106.7% |
| Q3 FY2022 | Sep 30, 2022 | $0.01 | -80.0% |
| Q2 FY2022 | Jun 30, 2022 | $0.13 | -27.8% |
| Q1 FY2022 | Mar 31, 2022 | $0.05 | -58.3% |
| Q3 FY2021 | Sep 30, 2021 | $0.30 | +150.0% |
| Q2 FY2021 | Jun 30, 2021 | $0.05 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.18 | – |
| Q4 FY2020 | Dec 31, 2020 | $0.12 | -42.9% |
| Q3 FY2020 | Sep 30, 2020 | $0.12 | +100.0% |
| Q2 FY2020 | Jun 30, 2020 | -$0.21 | -310.0% |
| Q1 FY2020 | Mar 31, 2020 | -$0.33 | – |
| Q4 FY2019 | Dec 31, 2019 | $0.21 | -64.4% |
| Q3 FY2019 | Sep 30, 2019 | $0.06 | -40.0% |
| Q2 FY2019 | Jun 30, 2019 | $0.10 | -9.1% |
| Q1 FY2019 | Mar 31, 2019 | -$0.08 | – |
| Q4 FY2018 | Dec 31, 2018 | $0.59 | – |
| Q3 FY2018 | Sep 30, 2018 | $0.10 | +42.9% |
| Q2 FY2018 | Jun 30, 2018 | $0.11 | 0.0% |
| Q1 FY2018 | Mar 31, 2018 | -$0.15 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.15 | -287.5% |
| Q3 FY2017 | Sep 30, 2017 | $0.07 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.11 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.03 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.08 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?